Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new collaborative study from the Oxford Parkinson’s Disease Centre has revealed that GABA transporters on astrocytes, the brain's lesser known yet critically important cells, support dopamine release and are sites of early dysfunction in parkinsonism.

Showing striatal immunofluorescence signals for astrocyte marker S100β and neuronal marker NeuN
Striatal immunofluorescence signals for astrocyte marker S100β (magenta) and neuronal marker NeuN (yellow)

The release of the neurotransmitter dopamine in the brain region called the striatum plays key roles in both our motivation and how we select our actions. This release is dysregulated across diverse disorders including Parkinson's and various addictions. Unravelling the mechanisms by which dopamine release in the striatum is governed, and understanding how these mechanisms might be dysfunctional in disease, is critical for identifying novel targets for disease-modifying therapies.

A new study funded by Parkinson's UK and published in Nature Communications, led by Department of Physiology, Anatomy & Genetic's Professor Stephanie Cragg and Dr Bradley Roberts, and in collaboration with the Oxford Parkinson’s Disease Centre, uncovers new observations about how non-neuronal cells in the brain, namely astrocytes, regulate striatal dopamine release and are sites of early dysfunction in Parkinson’s.

The full story is available on the Department of Physiology, Anatomy & Genetics website

 

Similar stories

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

World’s largest clinical trial for COVID-19 treatments expands internationally

Clinical Trials Coronavirus COVID-19 General

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.

Reprogramming tumour cells using an antimalarial drug

General Research

Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.